Herbert Eradat
Overview
Explore the profile of Herbert Eradat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mozas P, Ould Ammar R, Chartier L, Nastoupil L, Bachy E, Bezsera S, et al.
Br J Haematol
. 2025 Mar;
PMID: 40031898
The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL),...
2.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):175-204.
PMID: 38626800
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic...
3.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2022 Jun;
20(6):622-634.
PMID: 35714675
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as...
4.
Topp M, Eradat H, Florschutz A, Hochhaus A, Wrobel T, Walewski J, et al.
J Cancer Res Clin Oncol
. 2022 Feb;
149(2):811-817.
PMID: 35182224
Purpose: New therapies are needed for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based triplet combinations. Methods: Patients with R/R follicular lymphoma (FL; n = ...
5.
Horwitz S, Scarisbrick J, Dummer R, Whittaker S, Duvic M, Kim Y, et al.
Blood Adv
. 2021 Sep;
5(23):5098-5106.
PMID: 34507350
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting ≥4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice...
6.
Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Aug;
21(12):861-872.
PMID: 34389271
Background: CD19-directed chimeric antigen T-cell receptor (CAR-T) therapies have revolutionized the treatment of patients with relapsed/refractory (R/R) aggressive B-cell lymphomas (aBCL). The results of the landmark ZUMA-1 and JULIET trials...
7.
Kim Y, Prince H, Whittaker S, Horwitz S, Duvic M, Bechter O, et al.
Eur J Cancer
. 2021 Apr;
148:411-421.
PMID: 33794441
Introduction: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin...
8.
Dummer R, Prince H, Whittaker S, Horwitz S, Kim Y, Scarisbrick J, et al.
Eur J Cancer
. 2020 Jun;
133:120-130.
PMID: 32502876
Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 ...
9.
Montillo M, Illes A, Robak T, Pristupa A, Wach M, Egyed M, et al.
Health Qual Life Outcomes
. 2019 Nov;
17(1):173.
PMID: 31729982
Background: In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients...
10.
Eradat H
Curr Hematol Malig Rep
. 2019 Sep;
14(5):469-476.
PMID: 31512151
Purpose Of This Review: This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients...